Therapy Areas: Inflammatory Diseases
Elanco & Aratana partnership receives positive opinion for GALLIPRANT (grapiprant tablets) in Europe
13 November 2017 -

Elanco Animal Health and Aratana Therapeutics Inc (NASDAQ:PETX) on Friday jointly reported the European Medicine Agency's (EMA) positive opinion for the recommendation of the marketing authorisation of GALLIPRANT (grapiprant tablets) in the EU for the treatment of pain associated with mild to moderate osteoarthritis in dogs.

The European Medicine Agency (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) has adopted a positive opinion to recommend the marketing authorisation of GALLIPRANT (grapiprant tablets) in the EU.

In early 2018, the European Commission will complete the regulatory process for a final decision on the Marketing Authorisation of GALLIPRANT, added the company.

According to the company, Galliprant is a first-in-class veterinary medicine that will be indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Grapiprant, the active ingredient in Galliprant, is a non-steroidal non-cyclooxygenase inhibiting anti-inflammatory drug.

Under the terms of a prior agreement, Elanco has exclusive rights to develop, manufacture, market and commercialise Galliprant globally and co-promotes the product with Aratana in the US.

Elanco Animal Health provides products and services to improve animal health and food-animal production and is a division of Eli Lilly and Company (NYSE:LLY).

Login
Username:

Password: